Serum Lipoproteins Improve After Successful Pharmacologic Antidepressant Treatment

Hummel, Jana; Westphal, Sabine; Weber-Hamann, Bettina; Gilles, Maria; Lederbogen, Florian; Angermeier, Tobias; Luley, Claus; Deuschle, Michael; Kopf, Daniel

doi:10.4088/jcp.09m05853blu

Cited by 55 publications

(39 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent with earlier research indicating an association among low HDL, hypertriglyceridemia and clinical depression (Hummel et al, 2011;Scharnholz et al, 2014;van Reedt Dortland et al, 2010). The lack of an association between depression and obesity accords with a previous study using adolescent and elderly populations (Kuo et al, 2011), but other results are equivocal (Byers et al, 2012;Luppino et al, 2010;Scharnholz et al, 2014).…”

Section: Discussionsupporting

confidence: 92%

Depression trajectories and the association with metabolic adversities among the middle-aged adults

Kim

et al. 2015

Journal of Affective Disorders

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Depression trajectories and the association with metabolic adversities among the middle-aged adults

Kim

et al. 2015

Journal of Affective Disorders

View full text Add to dashboard Cite

“…Although other preclinical studies have not revealed any effect of venlafaxine on blood sugar level [9], our results present a significant decrease of blood glucose, despite of high triglyceride levels. This unexpected metabolic changes lead us to one possible explanation for the effect of venlafaxine on lipid and glucose homeostasis which means a presumptuous association between venlafaxine and peroxisome proliferator-activate receptor gamma (PPAR ) nuclear receptor.…”

Section: Discussioncontrasting

confidence: 36%

Metabolic Effects of Two Different Doses of Venlafaxine Therapy on Rats

Annamária

Kolcsár

Groşan

et al. 2015

Acta Medica Marisiensis

View full text Add to dashboard Cite

Objectives: Venlafaxine is an antidepressant, categorized as a serotonin-norepinephrine reuptake inhibitor (SNRI) with suspected metabolic side effects. The aim of our study was to assess these metabolic effects in rats, using two different doses of venlafaxine. Materials: Three groups of Wistar rats have been treated with venlafaxine during seven weeks. The rats have received a daily dose of 10mg/kg (D1) and 40 mg/ kg (D2) while the control group (Dc) has received no treatment. Rats were given "ad libitum" access to food and water. The rats were weighted at treatment day 0, 7, 14, 21, 28, 35, 42 and 49. After completion of venlafaxine treatment, the rats were sacrificed, blood was harvested and the following biochemical parameters have been determined from the centrifuged plasma: triglycerides, glucose and total cholesterol levels. Results: Both the 10 mg/kg and the 40 mg/kg dose venlafaxine therapy resulted in a highly significant increase of rat's weight. Compared with the control group the mean weight of D1 group has increased with 130.5 ±21.79 g (<0.01) while the mean weight of the second group increased with 94±24.16 g (p<0.01). In addition weight gain of D1 group was significantly higher than that of D2 group (p<0.01). Venlafaxine therapy induced significant increase in serum triglyceride levels (140.04±55.46 mg/dL p<0.01, 83.59±52.85 mg/dL p=0.05). This metabolic effect has been shown to be more evident in case of 10mg/kg dose therapy (p=0.03). Simultaneously, serum cholesterol levels have been reduced, however this decrease proved to be significant only in case of group D2 (p=0.03). Despite of increased triglyceride values, glucose levels were significantly decreased in both treated groups (133.33±36.18mg/dL p=0.05, 118.10±51.98 mg/dL p=0.02). Conclusions: Our results suggest that venlafaxine administrated to rats has unwished dose related metabolic effects such as significant increase in weight and hypertriglyceridemia, however serum cholesterol and plasma glucose levels appears to be decreased by this medication.

show abstract

“…Cholesterol was quantified by commercial enzymatic methods using a random-access analyser (Modular, Roche Diagnostics, Mannheim, Germany) as described by Hummel et al (2011). For quantification of HDL and LDL cholesterol, lipoprotein fractions were separated by ultracentrifugation over a time period of 18 h at 100.000 g in a 50.4 Ti rotor with a Beckman L-60 ultracentrifuge (Beckman Coulter, Munich, Germany).…”

Section: Laboratory Measurementsmentioning

confidence: 99%

“…Effective antidepressant pharmacotherapy modulates some of the dyslipidemic patterns observed in depressive patients, especially total cholesterol, HDL and LDL cholesterol (Hummel et al, 2011;Maes et al, 1997;Rabe-Jablonska and Poprawska, 2000). This may be a primary effect of the pharmacotherapy itself or may follow the amelioration of depressive symptoms.…”

Section: Introductionmentioning

confidence: 96%

Serum lipid profile changes after successful treatment with electroconvulsive therapy in major depression: A prospective pilot trial

Aksay

Bumb

Janke

et al. 2016

Journal of Affective Disorders

Self Cite

View full text Add to dashboard Cite

Serum Lipoproteins Improve After Successful Pharmacologic Antidepressant Treatment

Abstract: German Clinical Trial Registry Identifier: DRKS00000008.

Cited by 55 publications

References 0 publications

Depression trajectories and the association with metabolic adversities among the middle-aged adults

Depression trajectories and the association with metabolic adversities among the middle-aged adults

Metabolic Effects of Two Different Doses of Venlafaxine Therapy on Rats

Serum lipid profile changes after successful treatment with electroconvulsive therapy in major depression: A prospective pilot trial

Contact Info

Product

Resources

About